Literature DB >> 10518105

Prognostic factors after extended esophagectomy for squamous cell carcinoma of the thoracic esophagus.

M Tachibana1, S Kinugasa, D K Dhar, T Kotoh, M Shibakita, S Ohno, R Masunaga, H Kubota, H Kohno, N Nagasue.   

Abstract

BACKGROUNDS AND
OBJECTIVES: In Japan, extended esophagectomy with extensive lymphadenectomy has become the standard surgical procedure for carcinoma of the thoracic esophagus. Although mortality and morbidity rates after such extensive esophagectomy have been acceptable, the long-term outcomes are not necessarily satisfactory.
METHODS: Among 235 patients with primary squamous cell carcinoma of the thoracic esophagus between June 1981 and March 1998, 143 patients (60.9%) underwent extended esophagectomy with extensive lymphadenectomy. To exclude the effects of surgery-related postoperative complications, 14 patients who died within 90 days after operation were excluded. Thus, clinicopathological characteristics and prognostic factors of 129 patients were retrospectively investigated.
RESULTS: Sixty-three patients were alive and free of cancer. Sixty-six patients died: 37 of recurrence of the esophageal cancer and 29 of other causes. The 1-, 3-, 5-, and 10-year overall survival rates in the 129 patients were 78.8%, 53.5%, 45.8%, and 30.9%, respectively, and the disease-specific survival rates were 85.7%, 69.1%, 67.9%, and 56.2%, respectively. The factors influencing the disease-specific survival rate were tumor location (upper third vs. non-upper third), Borrmann classification (0, 1 vs. 2, 3), size of tumor (</=3.0 vs. >3.0 cm), depth of invasion (T1, 2 vs. T3, 4), number of lymph node metastases (0 or 1 vs. >/=2), time of operation (</=420 vs. >420 min), amount of blood transfused (</=2 vs. >/=3 U), lymph vessel invasion (marked vs. not marked), and blood vessel invasion (marked vs. not marked). Among those significant variables, independent prognostic factors for survival determined by multivariate analysis were number of lymph node metastases (P < 0.001), amount of blood transfusions (P = 0.0016), and tumor location (P = 0.0382).
CONCLUSIONS: Patients with a single metastatic node after extended esophagectomy should be considered to have excellent prognosis, like patients with pN0 tumors. Patients with multiple involved nodes should receive aggressive postoperative adjuvant treatments. Reduced blood loss during extended esophagectomy and minimal blood transfusions might improve the outcome of curative esophageal resections. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10518105     DOI: 10.1002/(sici)1096-9098(199910)72:2<88::aid-jso9>3.0.co;2-v

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Does fibrin glue reduce lymph leakage (pleural effusion) after extended esophagectomy? Prospective randomized clinical trial.

Authors:  Mitsuo Tachibana; Shoichi Kinugasa; Hiroshi Yoshimura; Dipok Kumar Dhar; Shuhei Ueda; Toshiyuki Fujii; Hitoshi Kohno; Naofumi Nagasue
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

2.  Laparoscopic esophagectomy in the palliative treatment of advanced esophageal cancer after radiochemotherapy.

Authors:  A Del Genio; G Rossetti; V Napolitano; V Maffettone; A Renzi; L Brusciano; G Russo; G Del Genio
Journal:  Surg Endosc       Date:  2004-10-26       Impact factor: 4.584

3.  Intraoperative blood transfusion contributes to decreased long-term survival of patients with esophageal cancer.

Authors:  Yoshihiro Komatsu; Hajime Orita; Mutsumi Sakurada; Hiroshi Maekawa; Toshitaka Hoppo; Koichi Sato
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

4.  18F-fluorodeoxyglucose positron emission tomography/computed tomography for the prediction of survival in patients with advanced esophageal cancer who have undergone neoadjuvant chemotherapy.

Authors:  Masahiko Yano; Hiroshi Miyata; Keijiro Sugimura; Masaaki Motoori; Takeshi Omori; Yoshiyuki Fujiwara; Norikatsu Miyoshi; Masayoshi Yasui; Masayuki Ohue; Hirofumi Akita; Akira Tomokuni; Hidenori Takahashi; Shogo Kobayashi; Masato Sakon
Journal:  Mol Clin Oncol       Date:  2018-01-10

5.  Tumour length as an independent prognostic factor in resectable oesophageal carcinoma.

Authors:  B Vadhwana; D Zosimas; P M Lykoudis; H M Phen; M Martinou; D Khoo
Journal:  Ann R Coll Surg Engl       Date:  2019-11-22       Impact factor: 1.891

6.  The prognostic value of tumor length to resectable esophageal squamous cell carcinoma: a retrospective study.

Authors:  Xiangwei Zhang; Yang Wang; Cheng Li; Jing Helmersson; Yuanzhu Jiang; Guoyuan Ma; Guanghui Wang; Wei Dong; Shaowei Sang; Jiajun Du
Journal:  PeerJ       Date:  2017-01-31       Impact factor: 2.984

7.  Application of single-port video-assisted thoracoscope in treating thoracic oesophageal squamous cell carcinoma using McKeown approach.

Authors:  Wenqiang Lv; Guiqing Zeng; Weibin Wu; Wuzhi Wei; Xiaodong Li; Wenke Yang
Journal:  J Minim Access Surg       Date:  2018 Apr-Jun       Impact factor: 1.407

8.  Tumor length in elderly patients with esophageal squamous cell carcinoma: is it a prognostic factor?

Authors:  Ji-Feng Feng; Ying Huang; Qiang Zhao
Journal:  Ups J Med Sci       Date:  2013-04-26       Impact factor: 2.384

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.